Stock Market Reviews

Stock Ticker News

Get the latest news, insights, and market updates on all tickers. Explore the news page 46 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Best Bookkeeping Software (Feb 2026): QuickBooks Recognized as Leading Digital Bookkeeping Tool for UK Businesses by Better Business Advice
  Better Business Advice has published its 2025 assessment of digital bookkeeping tools used by UK enterprises and highlighted QuickBooks as one of the leading solutions supporting financial management and regulatory compliance for small and medium-sized businesses. This showcases the role of cloud-based systems in providing streamlined processes, comprehensive reporting, and up-to-date financial visibility for UK businesses.
  Feb 21, 2026 - $INTU
• The Stock Market Just Did This for the First Time in Nearly a Year. History is Strikingly Clear About What Happens Next.
  Market gains have left some stocks trading at expensive levels.
  Feb 21, 2026 - $IONQ
• Goldman Sachs Initiates Coverage of Samsara Inc. (IOT) with a Buy Rating and a $36 Price Target
  Samsara Inc. (NYSE:IOT) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 11, 2026, Goldman Sachs analyst Matthew Martino initiated coverage of Samsara Inc. (NYSE:IOT) with a Buy rating and a $36 price target, calling it one of the “most defensible growth assets in software today.” The firm said Samsara is […]
  Feb 21, 2026 - $IOT
• Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating
  IQVIA Holdings Inc. (NYSE:IQV) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 11, 2026, Morgan Stanley lowered its price target on IQVIA Holdings Inc. (NYSE:IQV) to $240 from $265 but still maintained an Overweight rating, updating its estimates after the company’s quarterly results. On February 10, 2026, IQVIA Holdings Inc. […]
  Feb 21, 2026 - $IQV
• Why Integer Holdings Stock Flew Higher on Friday
  The company continued to bask in the afterglow of a double beat in its latest reported quarter.
  Feb 21, 2026 - $ITGR
• Jefferies Maintains an Underperform rating on Bloom Energy Corporation (BE)
  Bloom Energy Corporation (NYSE:BE) is among the Most Volatile Stocks. On February 10, 2026, Jefferies lifted Bloom Energy Corporation (NYSE:BE)’s price objective to $102 from $92 while retaining an Underperform rating. Jefferies claimed a $6 billion backlog for near-term visibility. The firm noted a lack of transparency on potential capacity expansions. On February 9, 2026, […]
  Feb 21, 2026 - $JEF
• Jefferies Raises its Price Target on The Williams Companies, Inc. (WMB) to $81 and Maintains a Buy Rating
  The Williams Companies, Inc. (NYSE:WMB) is among the 11 Best All-Time High Stocks to Buy According to Wall Street. On February 17, 2026, Jefferies raised its price target on The Williams Companies, Inc. (NYSE:WMB) to $81 from $78 and maintained a Buy rating following what Jefferies described as a “strong” analyst day update. Jefferies expects […]
  Feb 21, 2026 - $JEF
• Jefferies Turns Bullish on CoStar Group (CSGP), Citing Strong EBITDA Growth Outlook
  CoStar Group, Inc. (NASDAQ:CSGP) is included among the 14 Best Real Estate Stocks to Buy According to Hedge Funds. On February 20, Jefferies upgraded CoStar Group, Inc. (NASDAQ:CSGP) to Buy from Hold. It set a new price target of $67, down from $84. The firm said ongoing investor debate around Homes.com has created what it […]
  Feb 21, 2026 - $JEF
• Vast Takes a Giant Leap Towards Building a Private Space Station
  Dark horse space station company Vast gallops past its rivals with a big astronaut announcement.
  Feb 21, 2026 - $JHG
• FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
  The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma. FDA Designation The designation covers patients with cancer that is recurrent or metastatic and human papillomavirus (HPV)-unrelated after disease progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Johnson & Johnson’s (NYSE:JNJ) an
  Feb 21, 2026 - $JNJ